Attention Shareholders of Unicycive Therapeutics
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently the focus of an important notice. Recent developments urge shareholders to pay attention to their rights, especially for those who acquired shares during a specified class period. It’s crucial for shareholders to understand what steps they might need to take.
Understanding Your Rights as a Shareholder
For those who purchased shares of UNCY, it’s encouraged to reach out regarding potential lead plaintiff appointments. Importantly, you don't have to be appointed as a lead plaintiff to recover any losses you might have faced during the class period. Knowing your rights is the first step in addressing any grievances.
What is the Class Period?
The class period for this case spans from March 29, 2024, to June 27, 2025. Individuals who bought shares during this timeframe are particularly urged to file necessary registrations.
Allegations Highlighted in the Class Action
The allegations outline significant concerns regarding materially false and misleading statements made by Unicycive. Key points include claims that the company had overstated its readiness to meet the FDA's manufacturing compliance standards, and they also potentially misrepresented the regulatory prospects tied to their new drug application for oxylanthanum carbonate.
Why This Matters to You
For shareholders, understanding the implications of these allegations can be crucial. If you were misled by the representations made by Unicycive, taking timely action is essential to safeguard your investments.
Critical Deadline Approaching
Make note of the deadline: shareholders must act before October 14, 2025. Registering for this class action is a priority as the date is fast approaching. Failure to act may limit your options in seeking recovery.
Next Steps for Participating Shareholders
Once you have registered, you will gain access to updates regarding the case through a monitoring software tailored for enrolled shareholders. Keeping informed about the status of your case helps you make educated decisions moving forward, ensuring you remain engaged throughout.
Why Choose The Gross Law Firm?
The Gross Law Firm stands out as an advocate for shareholders, prioritizing the rights of investors affected by deception or misconduct in business practices. Their commitment is evident through their tireless work to promote transparency in corporate behavior. By choosing them, shareholders tap into a reservoir of expertise and a rich history in dealing with similar cases of class actions.
Contact Information for Further Assistance
If you need assistance or further clarity regarding your shareholder rights or wish to register for potential recovery, don’t hesitate to reach out. Here’s how you can contact The Gross Law Firm:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What should I do if I own shares of UNCY?
If you own shares of Unicycive Therapeutics, you should contact The Gross Law Firm to discuss your potential rights and options regarding recovery.
What is the class period for the lawsuit?
The class period for this lawsuit runs from March 29, 2024, to June 27, 2025.
What are the allegations against Unicycive Therapeutics?
The allegations include claims of materially misleading statements and overstatements regarding regulatory compliance and new drug applications.
When is the deadline for action?
The deadline for shareholders to act is October 14, 2025.
Can I participate in the case without being a lead plaintiff?
Yes, shareholders are encouraged to register even if they do not wish to be lead plaintiffs.
